Skip to content
Bharat Immunological & Biological Corporation logo

Bharat Immunological & Biological Corporation

524663 BSE
₹8.95 up 0.07 (0.79%)
Market Cap
₹38.67 Cr

Bharat Immunological & Biological Corporation (BIBCL) share price was ₹8.88 at the 28 Oct 2026 close; market capitalisation ₹38.37 Cr; sector Healthcare. The share price fell 56.9% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Sep 2023 quarter, revenue fell 100.0% year on year to under ₹0.1 Cr and net profit was −₹4.92 Cr, against −₹3.08 Cr a year earlier (compared with Sep 2022). Promoters held 59.25% of Bharat Immunological & Biological Corporation in Mar 2024, unchanged from Dec 2023. Its Tapetide Score is 40/100 (Weak) as of 28 Oct 2026.

Close 28 Oct 2026 ₹8.88 −12.15 −57.77% 1Y

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare
Market Cap
₹38.67 Cr
EBITDA
−₹15.70 Cr
Return on Equity
-19.43%
Debt to Equity
0.8
Book Value
−₹7.54
EPS (TTM)
−₹4.20
52W High
₹22.61
52W Low
₹7.11

Price-based figures as of 29 Oct 2026, 10:43 IST · TTM

Peer Comparison

Healthcare › Pharmaceuticals

Sun Pharma
₹1,764.0034.994,23,243 Cr5.060.91%13.79%17.94%61,848 Cr12,117 Cr
Divis Laboratories
₹9,667.5087.742,56,642 Cr15.310.32%15.32%18.96%11,682 Cr2,925 Cr
Torrent Pharmaceuticals
₹4,590.6072.071,74,612 Cr9.500.82%12.16%9.06%17,058 Cr2,156 Cr
Laurus Labs
₹2,194.10108.401,18,550 Cr22.370.09%16.38%19.67%7,323 Cr1,090 Cr
Zydus Life Science
₹1,183.9026.341,18,094 Cr4.360.09%16.99%19.24%28,515 Cr4,593 Cr
Dr Reddys Laboratories
₹1,338.7034.671,11,739 Cr2.880.61%10.87%13.94%34,247 Cr3,184 Cr
Cipla
₹1,365.7032.721,10,329 Cr3.120.96%11.21%14.88%28,589 Cr3,356 Cr
Bharat Immunological & Biological Corporation (this company)
₹8.95—39 Cr—0.00%-19.43%-16.78%9 Cr-18 Cr
Median 8 companies₹1,564.8534.991,18,322 Cr5.060.47%12.98%16.41%22,787 Cr3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

40 Weak
Overall score

Data confidence 88/100

Category scores

Quality Poor 34
Returns, margins, earnings quality 22% weight
Valuation Strong 74
Cheap vs sector & own history 24% weight
Growth Poor 1
Sales & profit trajectory 9% weight
Financial Health Poor 12
Solvency, leverage, coverage 9% weight
Momentum Poor 4
Trend strength, vol-adjusted 12% weight
Ownership Average 50
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Stock is trading at 0.41 times its book value

Weaknesses

4
  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of 5.09% over past five years.
  • Company has a low return on equity of -22.7% over last 3 years.
  • Debtor days have increased from 39.6 to 114 days.

Technical Indicators

Oscillators

Bullish

Bearish
0
Neutral
6
Bullish
3

Overall

Bearish

Bearish
10
Neutral
6
Bullish
3

Moving Averages

Bearish

Bearish
10
Neutral
0
Bullish
0

Growth Rate

Revenue Growth
-40.38% lower than 3Y

change over 1 year

Net Income Growth
94.32% higher than 3Y

change over 1 year

Cash Flow Change
126%

change over 1 year

EBITDA Margin Change
577%

change over 1 year

Quarterly Results

Particulars Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023
Sales
25.36
25.2
15.62
14.22
24.7
17.43
22.04
10.48
26.48
0
7.65
0
0
Expenses
29.86
27.47
31.54
13.18
28.19
16.41
25.71
15.31
28.98
4.72
11.67
4.31
4.68
Operating Profit
-4.5
-2.27
-15.92
1.04
-3.49
1.02
-3.67
-4.83
-2.5
-4.72
-4.02
-4.31
-4.68
OPM %
-17.74%
-9.01%
-101.92%
7.31%
-14.13%
5.85%
-16.65%
-46.09%
-9.44%
—
-52.55%
—
—
Other Income
0.14
1.2
9.08
0.25
0.22
0.12
0.59
0.14
0.32
0.1
0.49
0.1
0.16
Interest
1.17
1.3
1.22
1.16
1.23
1.54
1.68
1.58
1.74
1.67
2.06
1.72
2.09
Depreciation
0.06
0.06
0.06
0.06
0.06
0.04
0.05
0.04
0.04
0.04
0.09
0.03
0.03
PBT
-5.59
-2.43
-8.12
0.07
-4.56
-0.44
-4.81
-6.31
-3.96
-6.33
-5.68
-5.96
-6.64
Tax %
-30.77%
-21.81%
-19.46%
-2642.86%
105.26%
-25%
-11.02%
-20.76%
-22.22%
-26.07%
-31.69%
-23.15%
-26.05%
Net Profit
-3.87
-1.89
-6.53
1.93
-9.36
-0.33
-4.28
-5
-3.08
-4.68
-3.88
-4.59
-4.92
EPS (₹)
-0.9
-0.44
-1.51
0.45
-2.17
-0.08
-0.99
-1.16
-0.71
-1.08
-0.9
-1.06
-1.14
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Sales
46
173
203
146
128
124
35
84
67
85
78
45
8
Expenses
41
164
191
143
132
111
43
93
77
106
83
63
25
Operating Profit
6
9
12
3
-4
13
-8
-9
-10
-21
-5
-18
-18
OPM %
12%
5%
6%
2.3%
-3.1%
10%
-23%
-11%
-16%
-24%
-6%
-41%
-232%
Other Income
2
1
6
1
1
1
1
4
1
2
1
3
1
Interest
0
2
6
1
6
4
1
2
5
5
6
7
8
Depreciation
1
1
1
1
1
1
0
0
0
0
0
0
0
PBT
6
7
11
2
-9
9
-8
-7
-14
-24
-10
-23
-25
Tax %
-111%
27%
42%
26%
-31%
29%
-46%
-21%
-28%
-25%
-10%
-25%
—
Net Profit
13
5
6
2
-6
7
-4
-6
-10
-18
-9
-17
-18
EPS (₹)
2.91
1.16
1.48
0.36
-1.44
1.51
-0.99
-1.34
-2.36
-4.19
-2.03
-3.95
-4.18
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Sep 2023
Equity Capital
43
43
43
43
43
43
43
43
43
43
43
43
43
Reserves
-15
-1
-3
-2
-8
-1
-6
-12
-23
-9
62
45
36
Borrowings
7
0
-1
-9
9
0
0
32
3
27
78
70
74
Other Liabilities
45
48
52
48
24
17
16
62
103
43
29
28
35
Total Liabilities
81
90
91
80
68
59
53
125
127
104
213
186
188
Fixed Assets
9
8
7
6
6
5
5
5
4
4
116
115
115
CWIP
1
0
0
0
0
0
0
0
0
32
0
0
0
Investments
0
0
0
0
0
0
0
0
0
0
0
0
0
Other Assets
71
82
84
74
63
53
48
120
122
68
97
70
73
Total Assets
81
90
91
80
68
59
53
125
127
104
213
186
188
Figures in ₹ Crores

Cash Flow

Particulars Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Operating
5
31
-12
8
-9
-17
3
-32
34
12
-42
11
Investing
0
0
0
0
1
0
-1
1
1
1
1
0
Financing
-3
0
-6
-1
-2
-3
-1
31
-34
-12
45
-15
Net Cash Flow
2
31
-18
7
-10
-20
1
-1
1
0
3
-3
Free Cash Flow
5
32
-12
8
-9
-17
3
-32
34
12
-42
11
CFO/OP
89
338
-99
229
239
-132
-32
344
-328
-56
847
-59
Figures in ₹ Crores

Ratios

Particulars Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Debtor Days
209
2
47
34
37
19
167
318
96
0
5
114
Inventory Days
241
87
66
84
77
2
23
67
308
56
202
13
Days Payable
316
99
70
103
26
1
6
204
259
61
5
4
Cash Conversion Cycle
134
-9
43
16
88
19
185
181
145
-5
203
122
Working Capital Days
-20
-20
21
20
28
-19
59
10
-108
-174
-227
-549
ROCE %
20%
23%
42%
9%
-8%
31%
-18%
-11%
-22%
-46%
-3%
-9%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Bharat Immunological & Biological Corporation insights

62 extracted metrics + investor summaries across FY08–FY24.

Shareholding Pattern

Promot.59.25%Others1.28%Public39.47%As ofMar 2024

Documents

Frequently Asked Questions about Bharat Immunological & Biological Corporation

What does Bharat Immunological & Biological Corporation Ltd do?
Incorporated in 1989, Bharat Immunological and Biologicals Corporation Ltd manufactures biotechnology-based pharmaceuticals.[1]
Where is Bharat Immunological & Biological Corporation Ltd (BIBCL) listed?
Bharat Immunological & Biological Corporation Ltd trades under code 524663 on the BSE.
Which sector does Bharat Immunological & Biological Corporation Ltd belong to?
Bharat Immunological & Biological Corporation Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Bharat Immunological & Biological Corporation Ltd?
Bharat Immunological & Biological Corporation Ltd has a market capitalisation of ₹38.67 Cr as of 29 Oct 2026, which places it in the Small Cap band.
What is the 52-week high and low of Bharat Immunological & Biological Corporation Ltd?
Over the last 52 weeks Bharat Immunological & Biological Corporation Ltd has traded between ₹7.11 and ₹22.61 as of 29 Oct 2026.
What is the Return on Equity (ROE) of Bharat Immunological & Biological Corporation Ltd?
Bharat Immunological & Biological Corporation Ltd reported a return on equity of -19.43%. Its debt-to-equity ratio is 0.80.

Company Information

Incorporated in 1989, Bharat Immunological and Biologicals Corporation Ltd manufactures biotechnology-based pharmaceuticals.[1]

Website bibcol.com
Face Value ₹ 10
Shares Outstanding 4,32,04,420

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/524663.md for Bharat Immunological & Biological Corporation Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month